Century Therapeutics, Inc. filings document a biotechnology issuer developing iPSC-derived cell therapy programs for autoimmune diseases and cancer, along with the formal records supporting its public-company governance and capital structure. Form 8-K reports include operating and financial results, Regulation FD investor-presentation materials, clinical and regulatory program disclosures, and board composition changes.
Proxy and shareholder-vote materials cover annual meeting matters, board and committee governance, and charter-amendment voting, including reverse-stock-split authority. Capital-structure filings include shelf registration and at-the-market equity offering disclosures for common stock, while cover-page disclosures identify Century as an emerging growth company.
Century Therapeutics (IPSC) reported a third-quarter 2026 net loss of $23.453 million, compared with a $34.422 million net loss in the prior-year quarter. Collaboration revenue was $0 in both quarters, and operating expenses were $25.206 million versus $36.124 million. For the nine months ended September 30, 2026, the company reported no collaboration revenue and a net loss of $79.648 million, compared with $109.164 million in collaboration revenue and $9.591 million in net income in the same 2025 period.
Cash and cash equivalents were $45.016 million and total assets were $262.626 million as of September 30, 2026. Century said CNTY-813's IND submission remains on track for the fourth quarter of 2026 and CNTY-308's clinical trial is planned to initiate in 2026; it reported general alignment with the FDA for both programs. CNTY-813 data presented at EASD 2026 were described as further supporting advancement toward the clinic. Century appointed Joseph Truitt to its Board of Directors; he is Chief Executive Officer of iECURE, Inc. and Chairman of the Board of Larimar Therapeutics.
Century Therapeutics, Inc. (IPSC) reported a third-quarter net loss of $23.453 million, compared with $34.422 million a year earlier. For the nine months ended September 30, 2026, it recorded a $79.648 million net loss, versus $9.591 million net income in 2025; collaboration revenue was zero, compared with $109.164 million. The quarterly loss narrowed year over year, while the nine-month result shifted from profit to loss.
At September 30, 2026, cash, cash equivalents and investments totaled $174.125 million, while operating activities used $67.324 million in cash during the first nine months. A January private placement produced approximately $126.4 million in net proceeds. Based on current business plans, the company believes its resources can fund operating expenses and capital expenditures into the first quarter of 2029, but cautions that its assumptions may prove wrong and expenses and operating losses are expected to rise substantially. Century expects to submit an IND for lead candidate CNTY-813 in the fourth quarter of 2026; initial clinical data are anticipated in the second half of 2027, subject to remaining IND-enabling studies and regulatory clearance. It expects CNTY-308 to enter the clinic in 2026.
Century Therapeutics, Inc. (IPSC) SVP Finance & Operations Douglas Carr sold 266 shares of common stock on November 3, 2026, at $1.5190 per share. The shares were required to be sold to cover tax withholding obligations tied to restricted stock unit vesting; the sale was automatic and not at Carr’s discretion. Carr’s direct holdings after the transaction were 502,641 shares.
Century Therapeutics, Inc. (IPSC) officer Douglas Carr reported a proposed sale of 266 common shares for an aggregate market value of $403.94, with an approximate sale date of November 3, 2026. The sale includes an amount needed to cover a tax obligation from a vested equity award settlement; 266 shares were listed as acquired through restricted stock vesting on November 2, 2026. Carr's prior reported sales include three transactions during August and September 2026.
Century Therapeutics, Inc. (IPSC) presented nonclinical data for CNTY-813, its investigational iPSC-derived islet replacement therapy for type 1 diabetes, at the European Association for the Study of Diabetes meeting on October 2, 2026. In a diabetic mouse model, CNTY-813 maintained glycemic control for more than 11 months until graft removal. The presentation also reported consistent product across five clinical-scale runs, retained function after 96 hours of cold storage, and successful engraftment in rat livers using portal-vein delivery, the planned clinical route.
The company reported no tumorigenesis observed in more than 140 mice with more than 3 months of follow-up, with more than 1 billion cells infused. It said its CNTY-813 IND submission remains on track for Q4 2026 and anticipates initial clinical data in the second half of 2027. Century also said its pre-IND meeting with the FDA resulted in general alignment on the nonclinical package, Phase 1 manufacturing process and proposed Phase 1/2 trial design. These are preclinical findings; CNTY-813 is an investigational therapy.
Century Therapeutics, Inc. (IPSC) executive Gregory Russotti, Chief Technology and Manufacturing Officer, reported an automatic sale of 2,587 shares of common stock on September 14, 2026 at $1.93 per share. The footnote states these shares were sold solely to cover tax withholding obligations arising from the vesting of restricted stock units and the sale was not at his discretion.
After the transaction, Russotti holds 509,198 shares of Century Therapeutics common stock directly and 92,773 shares indirectly through the Gregory Russotti 2021 Family Trust. No Rule 10b5-1 trading plan is reported for this transaction.
Century Therapeutics, Inc. (IPSC) reported that Douglas Carr, its SVP Finance & Operations, sold 1,658 shares of common stock on September 14, 2026 at $1.93 per share. According to the company’s disclosure, these shares were sold automatically to cover tax withholding obligations from vesting restricted stock units, and Carr held 502,907 shares directly afterward.
Century Therapeutics, Inc. (IPSC) reported that President and CEO Brent Pfeiffenberger had 13,850 shares of common stock withheld on September 11, 2026 to satisfy tax withholding obligations related to the vesting of restricted stock units. After this tax-withholding disposition, he beneficially holds 3,633,839 common shares directly. No Rule 10b5-1 trading plan is reported.
Century Therapeutics, Inc. (IPSC) received a notice that officer Gregory Russotti intends to sell up to 2,587 shares of common stock under Rule 144, with an indicated aggregate market value of $4,994.20 as of September 14, 2026. The shares arise from restricted stock vesting treated as compensation from the issuer on September 11, 2026. A prior sale of 534 shares of common stock for $1,094.43 during the past three months is also reported, and the planned sale is stated to include an amount necessary to cover a tax obligation from settlement of the vested equity award.
Century Therapeutics, Inc. (IPSC) is the issuer for a planned sale of common stock reported on behalf of officer Douglas Carr under Rule 144. The notice covers up to 1,658 shares of common stock to be sold through Fidelity Brokerage Services LLC on NASDAQ, with an estimated aggregate sale price of $3,200.77.
The shares to be sold arise from restricted stock vesting on September 11, 2026, received from the issuer as compensation. In the prior three months, Carr reported additional sales of 275 shares on August 3, 2026 for $543.73 and 254 shares on September 8, 2026 for $520.57. A remark states that the sale includes shares to cover a tax obligation from settlement of a vested equity award distribution.